CN117257975A - 一种多功能细胞外囊泡及其制备方法和应用 - Google Patents
一种多功能细胞外囊泡及其制备方法和应用 Download PDFInfo
- Publication number
- CN117257975A CN117257975A CN202311565104.2A CN202311565104A CN117257975A CN 117257975 A CN117257975 A CN 117257975A CN 202311565104 A CN202311565104 A CN 202311565104A CN 117257975 A CN117257975 A CN 117257975A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- extracellular vesicles
- multifunctional
- targeting peptide
- extracellular vesicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 62
- 230000008685 targeting Effects 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 36
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 26
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000001301 oxygen Substances 0.000 claims abstract description 24
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 18
- 239000003636 conditioned culture medium Substances 0.000 claims description 15
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical group CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 201000011040 acute kidney failure Diseases 0.000 claims description 11
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 10
- 208000033626 Renal failure acute Diseases 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 230000008439 repair process Effects 0.000 claims description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003902 lesion Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 108010044426 integrins Proteins 0.000 abstract description 4
- 102000006495 integrins Human genes 0.000 abstract description 4
- 210000003470 mitochondria Anatomy 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 238000005316 response function Methods 0.000 abstract description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010038540 Renal tubular necrosis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- NGWWJSVRCMRJJM-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-(2-oxohydrazinyl)propanoic acid Chemical compound O=NN[C@H](C(=O)O)CC1=CC=C(O)C=C1 NGWWJSVRCMRJJM-QMMMGPOBSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003921 particle size analysis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- -1 nitrosotyrosine (nitrotyrosine) Chemical compound 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种多功能细胞外囊泡及其制备方法和应用,属于生物医药技术领域。本发明通过将抗炎细胞外囊泡与线粒体靶向肽基药偶联,得到的多功能细胞外囊泡能够解决现有技术中细胞外囊泡功能化产品功效单一、种类不足的问题。本发明提供的多功能细胞外囊泡有着环境可塑性、能够表达靶向炎症的整合素,具有定位于炎症病变的能力,可以靶向富集到炎症部位,还具有活性氧响应功能,可定点释放药物;本发明提供的多功能细胞外囊泡还具有协同的抗炎和抗氧化的治疗作用、具有保护线粒体功能和更强的器官保护作用。
Description
技术领域
本发明涉及生物医药技术领域,尤其涉及一种多功能细胞外囊泡及其制备方法和应用。
背景技术
细胞外囊泡(extracellular vesicles, EVs)是一种由细胞释放到细胞外基质的膜性小囊泡,参与细胞通讯、细胞迁移、血管新生和肿瘤细胞生长等过程,广泛地存在于各种体液和细胞上清中,并稳定携带了一些重要的信号分子。囊泡相关功能的研究已经成为研究热点,并有望在多种疾病的早期诊断中发挥作用。
为了达到更好的功效,现有技术公开了对细胞外囊泡进行功能化改进的多种技术方案,例如中国专利CN113616674A公开了一种具有抗炎作用的细胞外囊泡,具体为M2型巨噬细胞来源的胞外囊泡,通过实验证明M2型巨噬细胞来源的EVs具有免疫调节功能,发挥抗炎及促进组织修复的作用,在急性全身性炎症反应中具有潜在的治疗作用。
但是现有技术中的细胞外囊泡功能化产品存在功效单一、种类不足的问题。
发明内容
本发明的目的在于提供一种多功能细胞外囊泡及其制备方法和应用,以解决现有技术中细胞外囊泡功能化产品功效单一、种类不足的问题。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种多功能细胞外囊泡,所述多功能细胞外囊泡的结构中包含抗炎细胞外囊泡和偶联在抗炎细胞外囊泡表面的线粒体靶向肽基药。
优选的,所述抗炎细胞外囊泡与带有活性氧响应接头的线粒体靶向肽基药通过活性氧响应的化学接头实现偶联。
优选的,所述带有活性氧响应接头的线粒体靶向肽基药为DSPE-PEG-TK-SS31。
本发明还提供了上述多功能细胞外囊泡的制备方法,包括以下步骤:
将抗炎细胞外囊泡与带有活性氧响应接头的线粒体靶向肽基药进行共孵育,在此过程中,连接基团DSPE可插入抗炎细胞外囊泡的磷脂双分子层,使得抗炎细胞外囊泡与线粒体靶向肽基药偶联,得到多功能细胞外囊泡。
优选的,所述抗炎细胞外囊泡通过包含以下步骤的制备方法得到:
将炎症因子与间充质干细胞混合,进行预刺激;
预刺激后收集条件培养基;
将条件培养基中的抗炎细胞外囊泡进行分离。
优选的,所述炎症因子包括TNF-α、INF-γ和IL-1β;
所述TNF-α的浓度为1~100ng/mL;
所述INF-γ的浓度为1~100ng/mL;
所述IL-1β的浓度为1~100ng/mL;
所述预刺激的时间为12~72h。
优选的,所述带有活性氧响应接头的线粒体靶向肽基药为DSPE-PEG-TK-线粒体靶向肽。
优选的,所述线粒体靶向肽为SS-31肽。
优选的,所述DSPE-PEG-TK-线粒体靶向肽通过包含以下步骤的制备方法得到:
将DSPE-PEG-NH2和线粒体靶向肽通过ROS响应性连接剂进行连接,得到DSPE-PEG-TK-线粒体靶向肽。
本发明还提供了上述多功能细胞外囊泡、通过上述制备方法得到的多功能细胞外囊泡在制备抗炎药物、抗氧化药物、促修复药物或防治急性肾损伤药物中的应用。
本发明的有益效果:
本发明提供的多功能细胞外囊泡具有靶向炎症功能、有着环境可塑性、能够表达靶向炎症的整合素,具有定位于炎症病变的能力,可以靶向富集到炎症部位;所述多功能细胞外囊泡还具有活性氧响应功能,可定点释放药物;本发明提供的多功能细胞外囊泡还具有协同的抗炎和抗氧化的治疗作用,具备增强的抗炎疗效,可以减少炎症细胞浸润和炎症因子表达,发挥抗炎作用;还具有保护线粒体功能,发挥减轻氧化应激损伤作用,协同促进组织器官修复;另外具有增强的器官保护作用,细胞外囊泡与单独原料组分相比,进一步提高了肾功能、改善了肾脏病理损伤,发挥更优的保护作用。
附图说明
图1为三种细胞外囊泡合成图;
图2为三种细胞外囊泡微观形态图,其中A为细胞外囊泡(EV)电镜图;B为抗炎的细胞外囊泡(pEV)电镜图、C为多功能细胞外囊泡(pEV-TK-SS31)电镜图;
图3为三种细胞外囊泡粒径分布图,其中A为细胞外囊泡(EV)的粒径分析图;B为抗炎的细胞外囊泡(pEV)的粒径分析图;C为多功能细胞外囊泡(pEV-TK-SS31)的粒径分析图;
图4为动物肾脏内细胞外囊泡荧光成像图;
图5为细胞外囊泡荧光信号统计图;
图6为两种细胞外囊泡蛋白质组学检测图,其中A为抗炎细胞外囊泡(pEV)和细胞外囊泡(EV)做蛋白质组学的火山图;B为抗炎细胞外囊泡(pEV)和细胞外囊泡(EV)做蛋白质组学的差异蛋白热图;C为差异富集通路统计结果图;
图7为具有靶向和抗炎抗氧化功能的细胞外囊泡炎症富集图,其中A为免疫蛋白印迹结果,表明多功能细胞外囊泡高表达Integrin α4β1,B为粘附蛋白Integrin α4和Integrin β1组成的二聚体Integrin α4β1对炎症部位高表达的ICAM-1有高亲和性示意图;
图8为具有靶向和抗炎抗氧化功能的细胞外囊泡的活性氧响应性药物释放图;
图9为免疫荧光追踪共定位图及共定位分析图,其中A为免疫荧光追踪共定位图,B为信号共定位分析图;
图10为动物肾脏病理和肾脏功能指标图,其中A为周期性酸-希夫(PAS)染色结果图;B为急性肾小管坏死(ATN)评分分析结果图;C为血肌酐(SCr)评估结果图;D为血尿素氮(BUN)评估结果图;
图11为细胞外囊泡发挥抗炎和抗氧化协同作用图,其中A为巨噬细胞浸润的免疫荧光检测结果图;B为不同实验组对中性粒细胞浸润免疫荧光结果检测图;C为氧化应激损伤的标志物亚硝基酪氨酸(nitrotyrosine)的免疫荧光检测结果图;
图12为氧化应激损伤的标志物丙二醛(MDA)指标图。
具体实施方式
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
本发明提供了一种多功能细胞外囊泡,所述多功能细胞外囊泡的结构中包含抗炎细胞外囊泡和偶联在抗炎细胞外囊泡表面的线粒体靶向肽基药,所述抗炎细胞外囊泡与线粒体靶向肽基药优选通过活性氧响应的化学接头实现偶联,所述线粒体靶向肽基药优选为SS31。
本发明还提供了上述多功能细胞外囊泡的制备方法,包括以下步骤:
将抗炎细胞外囊泡与带有活性氧响应接头的线粒体靶向肽基药进行共孵育,连接基团DSPE可插入抗炎细胞外囊泡的磷脂双分子层,使得抗炎细胞外囊泡与线粒体靶向肽基药偶联,得到功能化细胞外囊泡,当采用DSPE-PEG-TK-SS31时,其与抗炎细胞外囊泡共孵育过程中DSPE通过疏水作用插入细胞外囊泡的磷脂双分子层,制备的功能化细胞外囊泡具有协同抗炎和抗氧化的治疗作用,促进组织器官修复。
所述抗炎细胞外囊泡优选通过包含以下步骤的制备方法得到:将炎症因子与间充质干细胞混合,进行预刺激;预刺激后收集条件培养基;将条件培养基中的抗炎细胞外囊泡进行分离,所述炎症因子优选包括TNF-α、INF-γ和IL-1β,所述TNF-α的浓度优选为1~100ng/mL;所述INF-γ的浓度优选为1~100ng/mL;所述IL-1β的浓度优选为1~100ng/mL;所述预刺激的时间优选为12~72h;所述预刺激的步骤是基于间充质干细胞的抗炎能力的可塑性具备的环境依赖特征,通过模拟急性肾损伤炎性微环境的策略“教育”间充质干细胞,进而制备得到抗炎细胞外囊泡。
在本发明中,所述带有活性氧响应接头的线粒体靶向肽基药优选为DSPE-PEG-TK-线粒体靶向肽,所述线粒体靶向肽优选为SS-31肽;
所述DSPE-PEG-TK-线粒体靶向肽优选通过包含以下步骤的制备方法得到:将DSPE-PEG-NH2和线粒体靶向肽通过ROS响应性连接剂进行连接,得到DSPE-PEG-TK-线粒体靶向肽。
本发明还提供了上述多功能细胞外囊泡、通过上述制备方法得到的多功能细胞外囊泡在制备抗炎药物、抗氧化药物、促修复药物或防治急性肾损伤药物中的应用;所得的细胞外囊泡具有利用组分之一的抗炎细胞外囊泡定位炎症病变的能力,可以靶向富集到炎症部位;细胞外囊泡的活性氧接头在组织损伤中被高表达的活性氧切割,可定点释放药物,协同抗炎和抗氧化的治疗作用以促进组织器官修复。
在本发明中,所述间充质干细胞与炎症因子混合之前优选包括以下步骤:使用培养基体外培养间充质干细胞,待间充质干细胞达到40%融合度时使用炎症因子预刺激间充质干细胞46~50h;然后利用pH=7.4的磷酸盐缓冲溶液清洗细胞两次并去除胎牛血清,收集条件培养基。
优选的,培养基为Dulbecco改良的Eagle's培养基,其含10%的胎牛血清和100U/mL的青霉素-链霉素;炎症因子包括1~100ng/mL的TNF-α、1~100ng/mL的INF-γ和1~100ng/mL的IL-1β;预刺激时间为48h。
优选的,去除胎牛血清的方法为:用去除细胞外囊泡的胎牛血清替换胎牛血清或者超速离心胎牛血清。
优选的,所述将条件培养基中的抗炎细胞外囊泡进行分离的步骤优选包括以下步骤:
将条件培养基在3~5℃及450~550×g条件下第一次离心8~12min;再在3~5℃及1500~2500×g条件下第二次离心15~25min;再在3~5℃及8000~12000×g条件下第三次离心25~35min;用0.22μm过滤器过滤后在3~5℃及80000~120000×g条件下第四次离心65~75min;弃掉上清液,用磷酸盐缓冲溶液重悬,再以80000~120000×g第五次离心1.5~2.5h;去除上清液后重悬于磷酸盐缓冲溶液中,并于-80℃温度下储存得抗炎细胞外囊泡。
优选的,第一次离心条件为4℃、500×g及10min;第二次离心条件为4℃、2000×g及20min;第三次离心条件为4℃、10000×g及30min;第四次离心条件为4℃、100000×g及70min;第五次离心条件为100000×g及2h。
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
1)使用含10%胎牛血清和100U/mL青霉素-链霉素的Dulbecco改良的Eagle's培养基体外培养间充质干细胞,待间充质干细胞达到40%融合度时,使用包含50ng/mL的TNF-α、50ng/mL的INF-γ和50ng/mL的IL-1β的炎症因子预刺激间充质干细胞48h;然后利用pH=7.4磷酸盐缓冲溶液清洗细胞两次,将普通10%胎牛血清换用商售的10%去除细胞外囊泡的胎牛血清,或者通过将普通胎牛血清超速离心(100000~120000×g,12h)获得去除细胞外囊泡的胎牛血清,再收集条件培养基;
2)将条件培养基在4℃及500×g条件下第一次离心10min;再在4℃及2000×g条件下第二次离心20min;再在4℃及10000×g条件下第三次离心30min;用0.22μm过滤器过滤;在4℃及100000×g条件下第四次离心70min;弃掉上清液,并用磷酸盐缓冲溶液重悬后,再以100000×g第五次离心2h;去除上清液后重悬于磷酸盐缓冲溶液中,用BCA试剂盒检测浓度,并于-80℃温度下储存得抗炎细胞外囊泡;
3)首先将羧基末端的酮缩硫醇(thioketal,TK)与DSPE-PEG2000-NH2通过氨基与羧基的缩合反应相连接,所得反应液用去离子水透析(MWCO,1000Da)纯化2天,然后冻干,制得DSPE-PEG2000-TK,所述TK与DSPE-PEG2000-NH2的投料摩尔比为1~100 : 1。随后将DSPE-PEG2000-TK和SS31进一步通过氨基与羧基的缩合反应相连接,所得反应液用去离子水透析(MWCO,1000Da)纯化2天,然后冻干,制得DSPE-PEG2000-TK-NHS,所述TK与DSPE-PEG2000-TK和SS-31的投料摩尔比为1 : 0.1~100。最后,将DSPE-PEG-TK-SS31与抗炎细胞外囊泡共孵育(4℃,6~24h或常温0.3~2h),DSPE通过疏水作用插入细胞外囊泡的磷脂双分子层,得到具有靶向和抗炎抗氧化功能的细胞外囊泡pEV-TK-SS31。
实施例2
1)使用含10%胎牛血清和100U/mL青霉素-链霉素的Dulbecco改良的Eagle's培养基体外培养间充质干细胞,待间充质干细胞达到40%融合度时,使用包含1ng/mL的TNF-α、1ng/mL的INF-γ和1ng/mL的IL-1β的炎症因子预刺激间充质干细胞46h;然后利用pH=7.4磷酸盐缓冲溶液清洗细胞两次,超速离心去除胎牛血清,再收集条件培养基;
2)将条件培养基在3℃及450×g条件下第一次离心12min;再在3℃及1500×g条件下第二次离心25min;再在3℃及8000×g条件下第三次离心35min;用0.22μm过滤器过滤;在3℃及80000×g条件下第四次离心75min;弃掉上清液,并用磷酸盐缓冲溶液重悬后,再以80000×g第五次离心2.5h;去除上清液后重悬于磷酸盐缓冲溶液中,用BCA试剂盒检测浓度,并于-80℃温度下储存得抗炎细胞外囊泡;
3)将酮缩硫醇分别与氨基末端的DSPE-PEG-NH2和含氨基的SS31多肽反应,得到具有ROS响应性的DSPE-PEG-TK-SS31,再将DSPE-PEG-TK-SS31与抗炎细胞外囊泡共孵育,DSPE通过疏水作用插入细胞外囊泡的磷脂双分子层,得到具有靶向和抗炎抗氧化功能的细胞外囊泡pEV-TK-SS31,此步骤与实施例1相同。
实施例3
一种具有靶向和抗炎抗氧化功能的细胞外囊泡,其经过以下步骤制得:
1)使用含10%去除细胞外囊泡的胎牛血清和100U/mL青霉素-链霉素的Dulbecco改良的Eagle's培养基体外培养间充质干细胞,待间充质干细胞达到40%融合度时,使用包含100ng/mL的TNF-α、100ng/mL的INF-γ和100ng/mL的IL-1β的炎症因子预刺激间充质干细胞50h;然后利用pH=7.4磷酸盐缓冲溶液清洗细胞两次,再收集条件培养基;
2)将条件培养基在5℃及550×g条件下第一次离心8min;再在5℃及2500×g条件下第二次离心15min;再在5℃及12000×g条件下第三次离心25min;用0.22μm过滤器过滤;在5℃及120000×g条件下第四次离心65min;弃掉上清液,并用磷酸盐缓冲溶液重悬后,再以120000×g第五次离心1.5h;去除上清液后重悬于磷酸盐缓冲溶液中,用BCA试剂盒检测浓度,并于-80℃温度下储存得抗炎细胞外囊泡;
3)将酮缩硫醇分别与氨基末端的DSPE-PEG-NH2和含氨基的SS31多肽反应,得到具有ROS响应性的DSPE-PEG-TK-SS31,再将DSPE-PEG-TK-SS31与抗炎细胞外囊泡共孵育,DSPE通过疏水作用插入细胞外囊泡的磷脂双分子层,得到具有靶向和抗炎抗氧化功能的细胞外囊泡pEV-TK-SS31,此步骤与实施例1相同。
对比例1
一种细胞外囊泡(EV),与实施例1相比,该细胞外囊泡未经过炎症教育策略培养和未连接线粒体靶向肽基药。
对比例2
一种抗炎细胞外囊泡(pEV),与实施例1相比,该细胞外囊泡未连接线粒体靶向肽基药,其余步骤与实施例1相同。
对比例3
一种抗炎细胞外囊泡(EV-TK-SS31),与实施例1相比,该细胞外囊泡未经过炎症教育策略培养,其余步骤与实施例1相同。
实验例
1、细胞外囊泡的合成与表征。对对比例1、对比例2以及实施例1的制备流程、微观形态以及粒径分布进行表征,结果分别如图1~3所示。
结果显示,工程化修饰后的细胞外囊泡仍然保持着细胞外囊泡的标志蛋白、粒径分布等性质。
2、细胞外囊泡的靶向性实验。体内分布实验,利用DiD标记分别标记对比例1及实施例1制备的细胞外囊泡,构建实施例1工程化细胞外囊泡pEV-TK-SS31,同时将对比例3工程化细胞外囊泡EV-TK-SS31作为对照;建立急性肾损伤模型后将两者进行尾静脉注射,于注射24h后处死动物,留取肾脏进行荧光成像。
结果如图4及图5所示,由实施例1抗炎细胞外囊泡组装的pEV-TK-SS31相对更多地积蓄在炎症肾脏,提示pEV-TK-SS31有炎症靶向性。
细胞外囊泡的膜蛋白介导其内吞摄取,有多项研究表明细胞外囊泡可以通过表面的粘附分子靶向到炎症部位。
因此,本发明将实施例1所制备的细胞外囊泡(pEV-TK-SS31)中决定与细胞的相互作用的组分-抗炎细胞外囊泡(pEV),和对比例1细胞外囊泡(EV)进行蛋白质组学检测聚焦关注粘附蛋白的差异表达。
结果如图6所示,蛋白质组学结果表明包括整合素在内的粘附蛋白是pEV的差异富集通路。如图7所示,pEV含有丰富的粘附蛋白Integrin α4和Integrin β1,Western blot验证了上述两个整合素蛋白的高表达。粘附蛋白Integrin α4和Integrin β1组成的二聚体Integrin α4β1对炎症部位高表达的ICAM-1具有高亲和性,因此表明富含Integrin α4β1的工程化细胞外囊泡pEV-TK-SS31可以靶向肾脏炎症区域,在肾脏炎症部位富集。
3、细胞外囊泡的活性氧响应性能实验。在实施例1细胞外囊泡pEV-TK-SS31中引入了对活性氧反应的结构(thioketal linker,TK linker),TK linker可在病变中被活性氧裂解以实现药物的按需释放(图8)。为了更好地证明TK连接体对活性氧反应性释放药物的能力,还合成了一个细胞外囊泡的类似物pEV-AA-SS31,即将TK linker替换成对活性氧不敏感的AA linker。评估了上述两者在细胞内的可控药物释放,pEV被phk26标记为红色,SS31被FITC替代用以可视化,利用免疫荧光以追踪二者在细胞内的定位。人肾小管上皮细胞(HK2 cells)利用或不利于活性氧刺激剂过氧化氢(H2O2)处理,同时用细胞外囊泡pEV-TK-FITC或pEV-AA-FITC治疗。
结果如图9所示,没有H2O2刺激时,无论是被TK linker还是被AA linker连接的pEV和FITC的信号都很好的重叠在一起,而存在H2O2损伤后,对活性氧不敏感的AA linker连接的pEV和FITC二者信号仍共定位,而被TK linker连接的pEV和FITC的信号不重叠,二者不存在共定位,表明TK linker被ROS裂解后pEV和FITC被释放,证实了TK linker的活性氧响应性。
4、细胞外囊泡对急性肾损伤的疗效实验。为了评估pEV-TK-SS31的治疗效果,建立了缺血/再灌注(I/R)诱导的急性肾损伤(I/R-AKI);组织病理学损伤通过周期性酸-希夫(PAS)染色进行评估。坏死以及死细胞脱落到肾小管管腔或变性蛋白质沉淀而形成的管型是肾脏损伤的重要标志(图10-A)。与假手术动物(Sham)相比,I/R组的广泛坏死(箭头所示)和管型形成(星号所示)都相当严重;经SS31、pEV或pEV-AA-SS31处理后,局灶性坏死和管型形成依然存在,而pEV-TK-SS31处理后,肾脏损伤明显减轻,坏死和管型形成更少,而且正常肾脏结构保存完好,近端肾小管刷状缘与假手术组的肾脏结构组相似。同样,急性肾小管坏死(ATN)评分分析也量化了肾小管损伤,并与上述观察结果一致(图10-B)。同时,还评估了肾功能的重要临床指标--血清肌酐(SCr)和血尿素氮(BUN)(图10-C及图10-D)。从SCr和BUN的增加可以看出,受到I/R损伤的小鼠出现了严重的肾功能障碍。相比之下,SS31、pEV或pEV-AA-SS31治疗可在一定程度上部分挽救肾功能,而pEV-TK-SS31治疗的效果更好。这些结果表明pEV-TK-SS31能在功能和组织病理学水平上更有效地减轻I/R引起的急性肾损伤。
5、细胞外囊泡的抗炎和抗氧化的疗效实验。检测pEV-TK-SS31对炎症和氧化应激的改善的作用,分别利用免疫荧光检测了急性肾损伤中炎症最常见的巨噬细胞(图11-A),结果表明,急性肾损伤(IR)组红色荧光标记的巨噬细胞相比假手术组明显增多,三个治疗组pEV、SS31和pEV-AA-SS31均对巨噬细胞浸润有一定缓解,而pEV-TK-SS31对减少巨噬细胞浸润疗效最好。类似的,pEV-TK-SS31也显示了对中性粒细胞浸润(图11-B)的改善,提示pEV-TK-SS31对炎症具有良好的治疗作用。
检测氧化应激损伤,亚硝基酪氨酸(nitrotyrosine)的产生代表氧化应激蛋白损伤,结果显示,单独使用SS31或pEV-AA-SS31可部分减少亚硝基酪氨酸的表达,而pEV-TK-SS31则几乎能完全消除亚硝基酪氨酸(图11-C)。与亚硝基酪氨酸减少同时出现的是脂质过氧化程度和细胞氧化损伤的另一个指标--MDA,pEV-TK-SS31也能很好地减少MDA的表达(图12)。上述结果证实,细胞外囊泡能发挥抗炎和抗氧化的协同作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种多功能细胞外囊泡,其特征在于,所述多功能细胞外囊泡的结构中包含抗炎细胞外囊泡和偶联在抗炎细胞外囊泡表面的线粒体靶向肽基药。
2.根据权利要求1所述的多功能细胞外囊泡,其特征在于,所述抗炎细胞外囊泡与带有活性氧响应接头的线粒体靶向肽基药通过活性氧响应的化学接头实现偶联。
3.根据权利要求1或2所述的多功能细胞外囊泡,其特征在于,所述线粒体靶向肽基药为带有活性氧响应接头的DSPE-PEG-TK-SS31。
4.权利要求1~3任一项所述的多功能细胞外囊泡的制备方法,其特征在于,包括以下步骤:
将抗炎细胞外囊泡与带有活性氧响应接头的线粒体靶向肽基药进行共孵育,使抗炎细胞外囊泡与线粒体靶向肽基药偶联,得到多功能细胞外囊泡。
5.根据权利要求4所述的多功能细胞外囊泡的制备方法,其特征在于,所述抗炎细胞外囊泡通过包含以下步骤的制备方法得到:
将炎症因子与间充质干细胞混合,进行预刺激;
预刺激后收集条件培养基;
将条件培养基中的抗炎细胞外囊泡进行分离。
6.根据权利要求5所述的多功能细胞外囊泡的制备方法,其特征在于,所述炎症因子包括TNF-α、INF-γ和IL-1β;
所述TNF-α的浓度为1~100ng/mL;
所述INF-γ的浓度为1~100ng/mL;
所述IL-1β的浓度为1~100ng/mL;
所述预刺激的时间为12~72h。
7.根据权利要求4所述的多功能细胞外囊泡的制备方法,其特征在于,所述带有活性氧响应接头的线粒体靶向肽基药为DSPE-PEG-TK-线粒体靶向肽。
8.根据权利要求7所述的多功能细胞外囊泡的制备方法,其特征在于,所述线粒体靶向肽为SS-31肽。
9.根据权利要求7所述的多功能细胞外囊泡的制备方法,其特征在于,所述DSPE-PEG-TK-线粒体靶向肽通过包含以下步骤的制备方法得到:
将DSPE-PEG-NH2和线粒体靶向肽通过ROS响应性连接剂进行连接,得到DSPE-PEG-TK-线粒体靶向肽。
10.权利要求1~3任一项所述的多功能细胞外囊泡、通过权利要求4~9任一项所述的制备方法得到的多功能细胞外囊泡在制备抗炎药物、抗氧化药物、促修复药物或防治急性肾损伤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311565104.2A CN117257975B (zh) | 2023-11-22 | 2023-11-22 | 一种多功能细胞外囊泡及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311565104.2A CN117257975B (zh) | 2023-11-22 | 2023-11-22 | 一种多功能细胞外囊泡及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117257975A true CN117257975A (zh) | 2023-12-22 |
CN117257975B CN117257975B (zh) | 2024-03-19 |
Family
ID=89216418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311565104.2A Active CN117257975B (zh) | 2023-11-22 | 2023-11-22 | 一种多功能细胞外囊泡及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117257975B (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619114A (zh) * | 2018-05-02 | 2018-10-09 | 东南大学 | 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用 |
CN112957478A (zh) * | 2021-02-09 | 2021-06-15 | 辽宁润基生物科技有限公司 | 一种细胞外囊泡(EVs)表面修饰靶向配体的方法 |
CN113186154A (zh) * | 2021-05-12 | 2021-07-30 | 浙江大学医学院附属邵逸夫医院 | 一种可调控骨关节炎的软骨细胞外泌体的制备方法 |
CN113274509A (zh) * | 2021-05-28 | 2021-08-20 | 广东药科大学 | 一种多肽药物纳米靶向给药系统HTPP-Exo-M1-8及其制备方法和应用 |
CN113616810A (zh) * | 2021-08-11 | 2021-11-09 | 南开大学 | 一种靶向p-选择素的工程化细胞外囊泡组合物及其制备方法和应用 |
CN114917202A (zh) * | 2022-05-26 | 2022-08-19 | 中国科学院深圳先进技术研究院 | 一种骨靶向细胞外囊泡及其制备方法和应用 |
WO2022223767A1 (en) * | 2021-04-23 | 2022-10-27 | Avulotion | Extracellular vesicles from mesenchymal stromal cells for treatment of diseases |
CN116036042A (zh) * | 2022-12-24 | 2023-05-02 | 江南大学 | 一种稳定的靶向m2型肿瘤相关巨噬细胞的外泌体纳米粒及制备方法及应用 |
CN116688101A (zh) * | 2023-06-26 | 2023-09-05 | 南通大学附属医院 | 高表达il-10中性粒细胞外囊泡在颞下颌骨关节炎治疗中的应用 |
CN116904394A (zh) * | 2023-08-10 | 2023-10-20 | 吉林大学 | 一种抗炎性间充质干细胞来源外泌体的制备方法及其应用 |
CN116942700A (zh) * | 2023-07-27 | 2023-10-27 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种多靶点修饰的工程化m2巨噬细胞外囊泡及其制备方法和应用 |
-
2023
- 2023-11-22 CN CN202311565104.2A patent/CN117257975B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619114A (zh) * | 2018-05-02 | 2018-10-09 | 东南大学 | 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用 |
CN112957478A (zh) * | 2021-02-09 | 2021-06-15 | 辽宁润基生物科技有限公司 | 一种细胞外囊泡(EVs)表面修饰靶向配体的方法 |
WO2022223767A1 (en) * | 2021-04-23 | 2022-10-27 | Avulotion | Extracellular vesicles from mesenchymal stromal cells for treatment of diseases |
CN113186154A (zh) * | 2021-05-12 | 2021-07-30 | 浙江大学医学院附属邵逸夫医院 | 一种可调控骨关节炎的软骨细胞外泌体的制备方法 |
CN113274509A (zh) * | 2021-05-28 | 2021-08-20 | 广东药科大学 | 一种多肽药物纳米靶向给药系统HTPP-Exo-M1-8及其制备方法和应用 |
CN113616810A (zh) * | 2021-08-11 | 2021-11-09 | 南开大学 | 一种靶向p-选择素的工程化细胞外囊泡组合物及其制备方法和应用 |
CN114917202A (zh) * | 2022-05-26 | 2022-08-19 | 中国科学院深圳先进技术研究院 | 一种骨靶向细胞外囊泡及其制备方法和应用 |
CN116036042A (zh) * | 2022-12-24 | 2023-05-02 | 江南大学 | 一种稳定的靶向m2型肿瘤相关巨噬细胞的外泌体纳米粒及制备方法及应用 |
CN116688101A (zh) * | 2023-06-26 | 2023-09-05 | 南通大学附属医院 | 高表达il-10中性粒细胞外囊泡在颞下颌骨关节炎治疗中的应用 |
CN116942700A (zh) * | 2023-07-27 | 2023-10-27 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种多靶点修饰的工程化m2巨噬细胞外囊泡及其制备方法和应用 |
CN116904394A (zh) * | 2023-08-10 | 2023-10-20 | 吉林大学 | 一种抗炎性间充质干细胞来源外泌体的制备方法及其应用 |
Non-Patent Citations (4)
Title |
---|
COLLINO FEDERICA ET AL.: "Extracellular Vesicles Derived from Induced Pluripotent Stem Cells Promote Renoprotection in Acute Kidney Injury Model", CELLS, 17 February 2020 (2020-02-17) * |
DI LIU ET AL.: "ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule", SCIENCE ADVANCES, pages 1 - 2 * |
EUN SOOK LEE ET AL.: "Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis", ACTA BIOMATERIALIA, pages 462 * |
HANZHANG ZHU ET AL.: "Light-activatable multifunctional paclitaxel nanoprodrug for synergistic chemo-photodynamic therapy in liver cancer", BIOFACTORS, pages 918 * |
Also Published As
Publication number | Publication date |
---|---|
CN117257975B (zh) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005070451A1 (en) | Pharmaceutical composition comprising non-glycosylated erythropoietin | |
WO2009043277A1 (fr) | Composition de soin cutané contenant une protéine de fusion hsa, son procédé de préparation et son utilisation | |
JPH11502413A (ja) | 分泌腺発現による遺伝子治療 | |
CN101711874A (zh) | 穿膜肽Tat介导的生长因子在透皮转运中的应用 | |
CN113088496A (zh) | Egf间充质干细胞外泌体及其制备方法和应用 | |
CN115025063A (zh) | 一种脑内皮细胞靶向仿生纳米递送系统及其制备方法与应用 | |
CN117257975B (zh) | 一种多功能细胞外囊泡及其制备方法和应用 | |
KR102386477B1 (ko) | 신규한 세포 투과성 펩타이드 및 이의 용도 | |
US11261222B2 (en) | Transdermal peptide with nuclear localization ability and use thereof | |
CN110179994A (zh) | 一种温度和酶双重响应性蛋白质高分子偶联物及其制备方法与应用 | |
CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
CN103083651A (zh) | 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用 | |
WO2023226203A1 (zh) | 一种骨靶向细胞外囊泡及其制备方法和应用 | |
CN114848610A (zh) | 一种外泌体-vegf-a纳米药物及其制备方法和应用 | |
Moss et al. | Ultrastructural immunogold studies of heparan sulphate proteoglycan in normal human glomeruli and glomerulonephritis | |
KR102285160B1 (ko) | 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물 | |
CN116004527A (zh) | 一种间充质干细胞凋亡小泡递释系统及其构建方法和应用 | |
CN108383912A (zh) | 人工融合蛋白及其用途 | |
CN107904251A (zh) | TAT‑hEGF融合蛋白的制备及其在隐形面膜的应用 | |
KR102274876B1 (ko) | 신규한 세포 투과성 펩타이드 및 이의 용도 | |
CN108949730A (zh) | 一种重组变构胶原酶的制备方法及其应用 | |
CN110404080B (zh) | 一种线粒体靶向的磷脂及其应用 | |
CN108939089B (zh) | 群体感应多肽及其在制备肿瘤靶向诊治递药系统中的用途 | |
CN111848736A (zh) | 自组装多肽、制备方法、自组装多肽制剂及应用 | |
CN112142856B (zh) | 一种用于改善脑卒中兴奋性毒性损伤的特异性降解ndrg2靶向肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |